Literature DB >> 16794372

Preventing skeletal complications in androgen deprived men with prostate cancer: Time for action.

M Braga-Basaria1, S Basaria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16794372     DOI： 10.1007/BF03344132

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  21 in total

Review 1.  Osteoporosis in men.

Authors:  E S Orwoll; R F Klein
Journal:  Endocr Rev       Date:  1995-02       Impact factor: 19.871

2.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma.

Authors:  J F Maillefert; J Sibilia; F Michel; C Saussine; R M Javier; C Tavernier
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

3.  Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists.

Authors:  S A Stoch; R A Parker; L Chen; G Bubley; Y J Ko; A Vincelette; S L Greenspan
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

4.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Authors:  M R Smith; F J McGovern; A L Zietman; M A Fallon; D L Hayden; D A Schoenfeld; P W Kantoff; J S Finkelstein
Journal:  N Engl J Med       Date:  2001-09-27       Impact factor: 91.245

5.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

6.  Osteoporosis after orchiectomy for prostate cancer.

Authors:  H W Daniell
Journal:  J Urol       Date:  1997-02       Impact factor: 7.450

7.  Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.

Authors:  M G Oefelein; V Ricchuiti; W Conrad; A Seftel; D Bodner; H Goldman; M Resnick
Journal:  J Urol       Date:  2001-11       Impact factor: 7.450

8.  Androgen deprivation therapy for prostate cancer results in significant loss of bone density.

Authors:  J T Wei; M Gross; C A Jaffe; K Gravlin; M Lahaie; G J Faerber; K A Cooney
Journal:  Urology       Date:  1999-10       Impact factor: 2.649

9.  Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.

Authors:  Daniella Mittan; Shuko Lee; Elizabeth Miller; Reina C Perez; Joseph W Basler; Jan M Bruder
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

10.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Authors:  Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450
View more
  1 in total

1.  Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy.

Authors:  Ellen F T Yee; Robert E White; Glen H Murata; Christine Handanos; Richard M Hoffman
Journal:  J Gen Intern Med       Date:  2007-07-17       Impact factor: 5.128
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.